Continucare Corp
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2006 |
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number 001-12115
CONTINUCARE CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
Florida
(State or other jurisdiction
of incorporation or organization)
|
|
59-2716023
(I.R.S. Employer Identification No.) |
7200 Corporate Center Drive
Suite 600
Miami, Florida 33126
(Address of principal executive offices)
(Zip Code)
(305) 500-2000
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and
(2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is a large filer, an accelerated filer or a
non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule
12b-2 of the Exchange Act.
Large accelerated filer o Accelerated filer o Non-accelerated filer x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes o No x
At November 2, 2006, the Registrant had 70,251,228 shares of $0.0001 par value common stock
outstanding.
CONTINUCARE CORPORATION
INDEX
2
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CONTINUCARE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
June 30, |
|
|
2006 |
|
2006 |
ASSETS
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
12,005,651 |
|
|
$ |
10,681,685 |
|
Other receivables, net |
|
|
317,942 |
|
|
|
231,832 |
|
Due from HMOs, net of a liability for incurred but not reported
medical claims expense of approximately $12,690,000 and
$14,207,000 at September 30, 2006 and June 30, 2006, respectively |
|
|
6,265,871 |
|
|
|
6,339,526 |
|
Prepaid expenses and other current assets |
|
|
547,838 |
|
|
|
689,096 |
|
Deferred tax assets, net |
|
|
658,768 |
|
|
|
658,768 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
19,796,070 |
|
|
|
18,600,907 |
|
Certificates of deposit, restricted |
|
|
1,145,130 |
|
|
|
1,126,987 |
|
Equipment, furniture and leasehold improvements, net |
|
|
1,057,021 |
|
|
|
824,220 |
|
Goodwill, net of accumulated amortization of approximately $7,610,000 |
|
|
14,342,510 |
|
|
|
14,342,510 |
|
Managed care contracts, net of accumulated amortization of
approximately $2,861,000 and $2,773,000 at September 30, 2006 and
June 30, 2006, respectively |
|
|
649,031 |
|
|
|
737,234 |
|
Deferred tax assets, net |
|
|
3,206,346 |
|
|
|
3,881,061 |
|
Other assets, net |
|
|
641,187 |
|
|
|
551,927 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
40,837,295 |
|
|
$ |
40,064,846 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
661,221 |
|
|
$ |
575,925 |
|
Accrued expenses and other current liabilities |
|
|
1,203,683 |
|
|
|
2,401,933 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
1,864,904 |
|
|
|
2,977,858 |
|
Capital lease obligations, less current portion |
|
|
139,274 |
|
|
|
112,068 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
2,004,178 |
|
|
|
3,089,926 |
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity: |
|
|
|
|
|
|
|
|
Common stock, $0.0001 par value: 100,000,000 shares authorized;
50,251,228 shares issued and outstanding at September 30, 2006
and 50,242,478 shares issued and outstanding at June 30, 2006 |
|
|
5,025 |
|
|
|
5,024 |
|
Additional paid-in capital |
|
|
64,299,128 |
|
|
|
63,838,051 |
|
Accumulated deficit |
|
|
(25,471,036 |
) |
|
|
(26,868,155 |
) |
|
|
|
|
|
|
|
|
|
Total shareholders equity |
|
|
38,833,117 |
|
|
|
36,974,920 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity |
|
$ |
40,837,295 |
|
|
$ |
40,064,846 |
|
|
|
|
|
|
|
|
|
|
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART
OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
3
CONTINUCARE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
September 30, |
|
|
2006 |
|
2005 |
Revenue: |
|
|
|
|
|
|
|
|
Medical services revenue, net |
|
$ |
35,881,917 |
|
|
$ |
29,729,636 |
|
Management fee revenue and other income |
|
|
51,682 |
|
|
|
141,514 |
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
35,933,599 |
|
|
|
29,871,150 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Medical services: |
|
|
|
|
|
|
|
|
Medical claims |
|
|
27,061,040 |
|
|
|
21,406,178 |
|
Other direct costs |
|
|
3,311,195 |
|
|
|
3,132,425 |
|
|
|
|
|
|
|
|
|
|
Total medical services |
|
|
30,372,235 |
|
|
|
24,538,603 |
|
|
|
|
|
|
|
|
|
|
Administrative payroll and employee benefits |
|
|
1,625,235 |
|
|
|
1,395,347 |
|
General and administrative |
|
|
1,836,359 |
|
|
|
1,702,206 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
33,833,829 |
|
|
|
27,636,156 |
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
|
2,099,770 |
|
|
|
2,234,994 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income |
|
|
154,122 |
|
|
|
59,141 |
|
Interest expense |
|
|
(2,934 |
) |
|
|
(2,969 |
) |
|
|
|
|
|
|
|
|
|
Income before income tax provision |
|
|
2,250,958 |
|
|
|
2,291,166 |
|
Income tax provision |
|
|
853,839 |
|
|
|
852,414 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,397,119 |
|
|
$ |
1,438,752 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
.03 |
|
|
$ |
.03 |
|
|
|
|
|
|
|
|
|
|
Diluted |
|
$ |
.03 |
|
|
$ |
.03 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
|
50,247,936 |
|
|
|
49,859,938 |
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
51,521,917 |
|
|
|
51,642,853 |
|
|
|
|
|
|
|
|
|
|
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART
OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
4
CONTINUCARE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
September 30, |
|
|
2006 |
|
2005 |
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net income |
|
$ |
1,397,119 |
|
|
$ |
1,438,752 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
170,834 |
|
|
|
157,382 |
|
Loss on disposal of fixed assets |
|
|
35,924 |
|
|
|
- |
|
Provision for bad debts |
|
|
50,225 |
|
|
|
12,463 |
|
Recognition of compensation expense related to issuance of stock options |
|
|
320,784 |
|
|
|
250,394 |
|
Deferred tax expense |
|
|
674,715 |
|
|
|
760,256 |
|
Changes in operating assets and liabilities, excluding the effect of disposals: |
|
|
|
|
|
|
|
|
Other receivables, net |
|
|
(136,335 |
) |
|
|
(49,996 |
) |
Due from HMOs, net |
|
|
73,655 |
|
|
|
(1,983,949 |
) |
Prepaid expenses and other current assets |
|
|
141,258 |
|
|
|
218,084 |
|
Other assets, net |
|
|
94,321 |
|
|
|
- |
|
Accounts payable |
|
|
85,296 |
|
|
|
(148,290 |
) |
Accrued expenses and other current liabilities |
|
|
(1,206,457 |
) |
|
|
(490,592 |
) |
|
|
|
|
|
|
|
|
|
Net cash provided by continuing operations |
|
|
1,701,339 |
|
|
|
164,504 |
|
Net cash used in discontinued operations |
|
|
- |
|
|
|
(30,972 |
) |
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
1,701,339 |
|
|
|
133,532 |
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Purchase of certificates of deposit |
|
|
(18,143 |
) |
|
|
(9,442 |
) |
Proceeds from sales of fixed assets |
|
|
25,000 |
|
|
|
- |
|
Purchase of property and equipment |
|
|
(319,326 |
) |
|
|
(28,085 |
) |
Acquisition
costs related to MDHC Companies |
|
|
(183,581 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(496,050 |
) |
|
|
(37,527 |
) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Repayments on note payable |
|
|
- |
|
|
|
(260,000 |
) |
Excess tax benefit from exercise of stock options |
|
|
125,419 |
|
|
|
- |
|
Principal repayments under capital lease obligations |
|
|
(21,617 |
) |
|
|
(18,489 |
) |
Proceeds from exercise of stock options |
|
|
14,875 |
|
|
|
358,668 |
|
Repurchase and retirement of common stock |
|
|
- |
|
|
|
(696,134 |
) |
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities |
|
|
118,677 |
|
|
|
(615,955 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
1,323,966 |
|
|
|
(519,950 |
) |
Cash and cash equivalents at beginning of period |
|
|
10,681,685 |
|
|
|
5,780,544 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
12,005,651 |
|
|
$ |
5,260,594 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Purchase of equipment, furniture and fixtures with proceeds of capital lease
obligations |
|
$ |
57,031 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
|
Cash paid for taxes |
|
$ |
30,000 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Cash paid for interest |
|
$ |
2,934 |
|
|
$ |
2,969 |
|
|
|
|
|
|
|
|
|
|
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART
OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
5
CONTINUCARE CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 UNAUDITED INTERIM INFORMATION
The accompanying unaudited condensed consolidated financial statements of Continucare Corporation
(Continucare or the Company) have been prepared in accordance with accounting principles
generally accepted in the United States for interim financial information and with the instructions
to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by accounting principles generally accepted in the United States
for complete financial statements. In the opinion of management, all adjustments (consisting of
normal recurring accruals) considered necessary for a fair presentation have been included.
Operating results for the three-month period ended September 30, 2006 are not necessarily
indicative of the results that may be reported for the remainder of the year ending June 30, 2007
or future periods. Except as otherwise indicated by the context, the terms the Company or
Continucare mean Continucare Corporation and its consolidated subsidiaries. All references to a
fiscal year refer to the Companys fiscal year which ends June 30. As used herein, Fiscal 2007
refers to the fiscal year ending June 30, 2007, Fiscal 2006 refers to the fiscal year ended June
30, 2006, and Fiscal 2005 refers to the fiscal year ended June 30, 2005.
The balance sheet at June 30, 2006 has been derived from the audited financial statements at that
date but does not include all of the information and footnotes required by accounting principles
generally accepted in the United States for complete financial statements.
For further information, refer to the consolidated financial statements and footnotes thereto
included in the Companys Annual Report on Form 10-K for Fiscal 2006. These interim condensed
consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes to consolidated financial statements included in that report.
Certain reclassifications have been made to the prior year amounts to conform to the current year
presentation.
NOTE 2 GENERAL
Continucare Corporation is a provider of primary care physician services on an outpatient basis in
Florida. The Company provides medical services to patients through employee physicians, advanced
registered nurse practioners and physicians assistants. Additionally, the Company provides
practice management services to independent physician affiliates (IPAs). Substantially all of
the Companys net medical services revenues are derived from managed care agreements with two
health maintenance organizations, Humana Medical Plans, Inc. (Humana) and Vista Healthplan of
South Florida, Inc. and its affiliated companies (Vista) (collectively, the HMOs). The Company
was incorporated in 1996 as the successor to a Florida corporation formed earlier in 1996.
In an effort to streamline operations and stem operating losses, the Company implemented a plan to
dispose of its home health operations in December 2003. The home health disposition occurred in
three separate transactions and was concluded in February 2004. As a result of these transactions,
the operations of the home health operations are shown as discontinued operations.
Effective January 1, 2006, the Company entered into an Independent Practice Association
Participation Agreement (the Risk IPA Agreement) with Humana under which the Company agreed to
assume certain management responsibilities on a risk basis for Humanas Medicare and Medicaid
members assigned to certain IPAs practicing in Miami-Dade and Broward Counties, Florida. During
the three-month period ended September 30, 2006, medical service revenue and medical services
expenses related to the Risk IPA Agreement approximated $4.0 million and $3.6 million,
respectively. The Risk IPA Agreement replaces the Physician Group Participation Agreement with
Humana (the Humana PGP Agreement) that was terminated effective December 31, 2005. Under the
Humana PGP Agreement, the Company assumed certain management responsibilities on a non-risk basis
for Humanas Medicare, Medicaid and commercial members assigned to selected primary care physicians
in Miami-Dade and Broward Counties, Florida. Revenue from this contract consisted of a monthly
management fee intended to cover
6
the costs of providing these services and amounted to approximately $0.1 million during the
three-month period ended September 30, 2005.
Effective as of October 1, 2006, the Company acquired Miami Dade Health Centers, Inc. and its
affiliated companies (collectively, the MDHC Companies). See Note 9 for a description of this
transaction.
NOTE 3 RECENT ACCOUNTING PRONOUNCEMENTS
In May 2005, the Financial Accounting Standards Board (FASB) issued Statement of Financial
Accounting Standards (SFAS) No. 154, Accounting Changes and Error Corrections-a Replacement of
APB Opinion No. 20 and FASB Statement No. 3 (SFAS 154). SFAS 154, which replaces APB Opinion
No. 20, Accounting Changes, and SFAS No. 3, Reporting Accounting Changes in Interim Financial
Statements, changes the requirements for the accounting and reporting of a change in an accounting
principle. The statement requires retrospective application of changes in an accounting principle
to prior periods financial statements unless it is impracticable to determine the period-specific
effects or the cumulative effect of the change. SFAS 154 is effective for accounting changes and
corrections of errors made in fiscal years beginning after December 15, 2005. The adoption of SFAS
154 did not have a material impact on the Companys financial position, results of operations or
cash flows, for the three-months ended September 30, 2006.
In July 2006, the FASB issued Interpretation No. 48 Accounting for Uncertainty in Income Taxes
(FIN 48) to clarify the accounting for uncertainties related to income taxes that are recognized
in an enterprises financial statements in accordance with SFAS 109, Accounting for Income Taxes.
This interpretation prescribes a recognition threshold and measurement attribute for the financial
statement recognition and measurement of a tax position taken or expected to be taken in a tax
return. The evaluation of a tax position in accordance with FIN 48 is a two-step process. The
first step is recognition, which requires an enterprise to determine whether it is more likely than
not that a tax position will be sustained upon examination based on the technical merits of the
position. The second step is measurement, which requires a company to recognize a tax position
that meets the more-likely-than-not recognition threshold at the largest amount of benefit that is
greater than fifty percent likely of being realized upon ultimate settlement. FIN 48 is effective
as of the beginning of the first annual reporting period that begins after December 15, 2006. The
Company is currently assessing FIN 48 and is currently evaluating the impact it will have on its
results of operations and financial condition.
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157
defines fair value, establishes a framework for measuring fair value in accordance with accounting
principles generally accepted in the United States, and expands disclosures about fair value
measurements. The provisions of SFAS 157 are effective for fiscal years beginning after November
15, 2007. The Company is currently evaluating the impact, if any, of the provisions of SFAS 157.
In September 2006, the SEC issued Staff Accounting Bulletin No. 108 (SAB 108), which added
Section N to Topic 1, Financial Statements, of the Staff Accounting Bulletin Series. Section N
provides guidance on the consideration of the effects of prior year misstatements when quantifying
current year financial statement misstatements for the purpose of materiality assessment. The SEC
concluded in SAB 108 that a registrants materiality evaluation of an identified unadjusted error
should quantify the impact of correcting all misstatements, including both the carryover and
reversing effects of prior year misstatements, on the current year financial statements. If either
carryover or reversing effects of prior year misstatements is material, the misstatements should be
corrected in the current year. If correcting an error in the current year for prior year
misstatements causes the current year to be materially misstated, the prior year financial
statements should be corrected, even though such revision previously was and continues to be
immaterial to the prior year financial statements. Correcting prior year financial statements for
immaterial errors would not require previously filed reports to be amended. Such correction may be
made the next time the registrant files the prior year financial statements. The guidance of SAB
108 should be applied in the annual financial statements covering the fiscal year ending June 30,
2007. The Company does not believe SAB 108 will have a material
impact on the Companys consolidated financial position, results
of operations or cash flows.
7
NOTE 4 STOCK-BASED COMPENSATION
The Amended and Restated Continucare Corporation 2000 Stock Incentive Plan (the 2000 Stock
Incentive Plan), which was approved by the Companys shareholders, permits the grant of stock
options and restricted stock awards in respect of up to 7,000,000 shares of common stock to the
Companys employees, directors, independent contractors and consultants. Under the terms of the
2000 Stock Incentive Plan, options are granted at the fair market value of the stock at the date of
grant and expire no later than ten years after the date of grant. Options granted under the plan
generally vest over four years, but the terms of the 2000 Stock Incentive Plan provide for
accelerated vesting if there is a change in control of the Company. Historically, the Company has
issued authorized but previously unissued shares of common stock upon option exercises. However,
the Company does not have a policy regarding the issuance or repurchase of shares upon option
exercise or the source of those shares. No restricted stock awards have been issued under the 2000
Stock Incentive Plan.
Prior to July 1, 2005, the Company followed Accounting Principles Board Opinion No. 25, (APB No.
25), Accounting for Stock Issued to Employees, and related Interpretations in accounting for its
employee stock options. Under APB No. 25, when the exercise price of the Companys employee stock
options equaled or exceeded the market price of the underlying stock on the date of grant, no
compensation expense was recognized. Stock options issued to independent contractors or
consultants were accounted for in accordance with Statement of Financial Accounting Standards
(SFAS) No. 123, (SFAS No. 123), Accounting for Stock-Based Compensation.
Effective July 1, 2005, the Company adopted SFAS No. 123(R), Share-Based Payment, which is a
revision of SFAS No. 123, using the modified prospective transition method. Under this method,
compensation cost recognized for the three-month periods ended September 30, 2006 and 2005 include:
(a) compensation cost for all share-based payments modified or granted prior to, but not yet vested
as of July 1, 2005, based on the grant date fair value estimated in accordance with the original
provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted
subsequent to July 1, 2005, based on the grant date fair value estimated in accordance with the
provisions of SFAS No. 123(R). Results for periods prior to July 1, 2005 have not been restated.
The Company calculates the fair value for employee stock options using a Black-Scholes option
pricing model at the time the stock options are granted and that amount is amortized over the
vesting period of the stock options, which is generally up to four years. The fair value for
employee stock options granted during the three-month periods ended September 30, 2006 and 2005 was
calculated based on the following assumptions: risk-free interest rate ranging from 5.08% to 5.16%
and 4.21% to 4.35%, respectively; dividend yield of 0%; volatility factor of the expected market
price of the Companys common stock of 64.9% and 74.8%, respectively; and weighted-average expected
life of the options ranging from 3 to 6 years depending on the vesting provisions of each option.
The expected life of the options is based on the historical exercise behavior of the Companys
employees. The expected volatility factor is based on the historical volatility of the market
price of the Companys common stock as adjusted for certain events that management deemed to be
non-recurring and non-indicative of future events.
As a result of adopting SFAS No. 123(R), for the three-month periods ended September 30, 2006 and
2005, the Company recognized share-based compensation expense of $0.3 million and $0.2 million,
respectively. The adoption of Statement 123(R) had no effect on cash flow from operations for the
three-month periods ended September 30, 2006 and 2005. In accordance with SFAS 123(R), cash flows
from financing activities for the three-month period ended September 30, 2006 included
approximately $0.1 million of excess tax benefits resulting from the exercise of stock options. For
the three-month period ended September 30, 2005, the Company had net operating loss carryforwards
and did not recognize any tax benefits resulting from the exercise of stock options because the
related tax deductions would not have resulted in a reduction of income taxes payable. During the
three-month periods ended September 30, 2006 and 2005, the Company issued 8,750 shares and 366,667
shares, respectively, of common stock resulting from the exercise of stock options.
8
The following table summarizes information related to the Companys stock option activity for the
three-month period ended September 30, 2006:
|
|
|
|
|
|
|
|
|
|
|
Number |
|
Weighted Average |
|
|
of Shares |
|
Exercise Price |
Outstanding at beginning of the period |
|
|
3,659,304 |
|
|
$ |
1.56 |
|
Granted |
|
|
410,000 |
|
|
$ |
2.77 |
|
Exercised |
|
|
(8,750 |
) |
|
$ |
1.70 |
|
Forfeited |
|
|
(31,250 |
) |
|
$ |
1.70 |
|
|
|
|
|
|
|
|
|
|
Outstanding at end of the period |
|
|
4,029,304 |
|
|
$ |
1.68 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at end of the period |
|
|
2,292,968 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average fair value per share
of options granted during the period |
|
$ |
1.52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average fair value per share of options granted during the three-month period ended
September 30, 2005 was $1.41.
The following table summarizes information about options outstanding and exercisable at September
30, 2006:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding |
|
Options Exercisable |
Range of |
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
|
|
Weighted Average |
Exercise |
|
|
|
|
|
Weighted Average |
|
Remaining |
|
Number |
|
Weighted Average |
|
Remaining |
Prices |
|
Number Outstanding |
|
Exercise Price |
|
Contractual Life |
|
Exercisable |
|
Exercise Price |
|
Contractual Life |
$1.98-$2.99
|
|
|
1,855,000 |
|
|
$ |
2.47 |
|
|
|
8.9 |
|
|
|
495,833 |
|
|
$ |
2.31 |
|
|
|
8.1 |
|
$0.66-$1.70
|
|
|
2,174,304 |
|
|
$ |
1.00 |
|
|
|
6.6 |
|
|
|
1,797,135 |
|
|
$ |
0.87 |
|
|
|
6.3 |
|
The total intrinsic value of options outstanding and options exercisable was $3.3 million and $3.0
million, respectively, at September 30, 2006. The total intrinsic value of options exercised during
the three-month periods ended September 30, 2006 and 2005 was approximately $9,000 and $0.5
million, respectively.
As of September 30, 2006, there was approximately $1.6 million of total unrecognized compensation
cost related to non-vested stock options, which is expected to be recognized over a
weighted-average period of 2.2 years. In connection with the Acquisition, the Company granted each
of the three principal owners of the MDHC Companies options to acquire 100,000 shares of the
Companys common stock at a per share exercise price equal to the closing price of the Companys
common stock on October 2, 2006 (the first trading day after completion of the Acquisition). The
options vest ratably over four years and have a term of ten years. See Note 9 for a description of
the Acquisition.
The Company has 760,000 warrants outstanding at September 30, 2006 which are exercisable through
December 31, 2007, with exercise prices ranging from $7.25 to $12.50 per share.
Shares of common stock have been reserved for future issuance at September 30, 2006 as follows:
|
|
|
|
|
Warrants |
|
|
760,000 |
|
Stock options |
|
|
5,738,221 |
|
|
|
|
|
|
Total |
|
|
6,498,221 |
|
|
|
|
|
|
9
NOTE 5 CREDIT FACILITY
The Company has in place a credit facility that provides for a revolving loan to the Company of
$5.0 million (the Credit Facility). Effective March 8, 2006, the maturity date of the Credit
Facility was extended until September 30, 2007, the maximum amount available for borrowing under
the Credit Facility was increased from $3,000,000 to $5,000,000, and the interest rate under the
Credit Facility was reduced to the sum of 2.5% plus the 30-day Dealer Commercial Paper Rate.
In connection with the acquisition of the MDHC Companies, on September 26, 2006 the Company
modified its Credit Facility to, among other things, provide that the interest rate payable on
borrowings under the Credit Facility is 2.4% plus the One-Month LIBOR rate, and the Company entered
into certain additional lines of credit to finance the acquisition of the MDHC Companies. At
September 30, 2006, there was no outstanding principal balance on the Credit Facility. Interest
under the Credit Facility is payable monthly and was 7.72% at September 30, 2006. All assets of
the Company serve as collateral for the Credit Facility. See Note 9 for increase in consolidated
net indebtedness of the Company effective October 1, 2006 and additional amendments to the terms of
the Credit Facility.
NOTE 6 EARNINGS PER SHARE
A reconciliation of the denominator of the basic and diluted earnings per share computation is as
follows:
|
|
|
|
|
|
|
|
|
|
|
Three-Months Ended September 30, |
|
|
2006 |
|
2005 |
Basic weighted average number of shares outstanding |
|
|
50,247,936 |
|
|
|
49,859,938 |
|
Dilutive effect of stock options |
|
|
1,273,981 |
|
|
|
1,705,270 |
|
Dilutive effect of convertible debt |
|
|
- |
|
|
|
77,645 |
|
|
|
|
|
|
|
|
|
|
Diluted weighted average number of shares
outstanding |
|
|
51,521,917 |
|
|
|
51,642,853 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Not included in calculation of diluted earnings
per share as impact is antidilutive: |
|
|
|
|
|
|
|
|
Stock options outstanding |
|
|
595,000 |
|
|
|
334,000 |
|
Warrants |
|
|
760,000 |
|
|
|
760,000 |
|
NOTE 7 INCOME TAXES
The Company accounts for income taxes under FASB Statement No. 109, Accounting for Income Taxes.
Deferred income tax assets and liabilities are determined based upon differences between the
financial reporting and tax bases of assets and liabilities and are measured using the enacted tax
rates and laws that will be in effect when the differences are expected to reverse.
The
Company recorded an income tax provision of $853,839 and $852,414 for the three-month periods
ended September 30, 2006 and 2005, respectively.
NOTE 8 CONTINGENCIES
The MDHC Companies have received two Notices of Intent to Initiate Litigation for Medical
Negligence from legal counsel to former patients. Formal legal proceedings have not yet been
initiated. Management cannot predict the outcome of these matters or the liability to the Company,
if any, if they are not resolved in the Companys favor.
The Company is also involved in other legal proceedings incidental to its business that arise from
time to time out of the ordinary course of business including, but not limited to, claims related
to the alleged malpractice of employed and contracted medical professionals, workers compensation
claims and other employee-related matters, and minor disputes with equipment lessors and other
vendors. The Company records an accrual for medical malpractice claims,
10
which includes amounts for insurance deductibles and projected exposure, based on our estimate of
the ultimate outcome of such claims, if any.
NOTE 9 ACQUISITION
Effective October 1, 2006, the Company completed its acquisition of the MDHC Companies (the
Acquisition). In connection with the completion of the Acquisition and in consideration for the
assets acquired pursuant to the Acquisition, the Company paid the MDHC Companies approximately $5.0
million in cash, issued to the MDHC Companies 20.0 million shares of the Companys common stock,
par value $.0001 per share, and assumed or repaid certain indebtedness and liabilities of the MDHC
Companies. The 20.0 million shares of the Companys common stock issued in connection with the
Acquisition were issued pursuant to an exemption under the Securities Act of 1933, as amended, and
1.5 million of such 20.0 million shares were placed in escrow as security for indemnification
rights of the MDHC Companies and their principal owners, and, in November 2006, 248,661 of such
shares were cancelled in connection with a post-closing purchase price adjustment. Pursuant to the
terms of the Acquisition, the Company is also obligated to pay the principal owners of the MDHC
Companies an additional $1.0 million in cash on October 1, 2007, the first anniversary date of the
closing, and up to $2.0 million in cash based on the working capital of the MDHC Companies as of
October 1, 2006 and the monthly payments in respect of the MDHC Companies business operations
received by the Company or any of its subsidiaries from certain identified third-party payors
during the fourteen day period commencing on October 1, 2006. The Company will also make certain
other payments to the principal owners of the MDHC Companies depending on the collection of certain
receivables that were fully reserved on the books of the MDHC Companies as of December 31, 2005.
The purchase price, including acquisition costs, will be allocated to the estimated fair values of
assets acquired and liabilities assumed as of October 1, 2006.
On September 26, 2006, Continucare MDHC, LLC, a wholly-owned subsidiary of the Company
(Borrower), entered into two term loan facilities funded out of lines of credit (the Term
Loans) with maximum loan amounts of $4.8 million and $1.0 million, respectively. Each of the Term
Loans requires Borrower to make mandatory monthly payments that reduce the lines of credit under
the Term Loans. Subject to the terms and conditions of the Term Loans, any prepayments made to the
Term Loans by Borrower may be re-borrowed by Borrower on a revolving basis so long as the line of
credit applicable to such Term Loan, as reduced by the mandatory monthly payment, is not exceeded.
Each of the Term Loans (a) matures on October 1, 2011, (b) has variable interest rates at a per
annum rate equal to the sum of 2.4% and the One-Month LIBOR rate, (c) requires the Company and its
subsidiaries, on a consolidated basis, to maintain a tangible net worth of $12 million and a debt
coverage ratio of 1.25 to 1 and (d) are secured by substantially all of the assets of the Company
and its subsidiaries, including those assets acquired pursuant to the Acquisition. Effective
October 1, 2006, Borrower fully drew on these Term Loans to fund certain portions of the cash
payable upon the closing of the Acquisition.
Also effective September 26, 2006, the Company amended the terms of its existing Credit Facility to
eliminate the financial covenant which previously required the Companys EBITDA to exceed
$1,500,000 on a trailing 12-month basis any time during which amounts are outstanding under the
Credit Facility and replace such covenant with covenants requiring the Company and its
subsidiaries, on a consolidated business, to maintain a tangible net worth of $12 million and a
debt coverage ratio of 1.25 to 1. Effective October 1, 2006, the Company drew approximately $1.8
million under the Credit Facility to fund portions of the cash payable upon the closing of the
Acquisition.
As a result of the Acquisition, the consolidated net indebtedness of the Company increased by
approximately $7.6 million. However, since the closing of the Acquisition, the Company has repaid
substantially all of that increased indebtedness, and such amounts are now available for future
borrowing.
In connection with the Acquisition, the Company appointed Dr. Luis Cruz to the Companys Board of
Directors effective as of October 1, 2006 and entered into one-year employment agreements with each
of the principal owners of the MDHC Companies. Under these employment agreements, Dr. Luis Cruz is
employed as Vice Chairman of the Board of Directors of the Company at an annual salary of $225,000,
Jose Garcia is employed as Executive Vice President of the Company at an annual salary of $275,000,
and Carlos Garcia is employed as President Diagnostics Division of the Company at an annual
salary of $225,000. Each of the three principal owners of the MDHC
11
Companies was also awarded options to acquire 100,000 shares of the Companys common stock at a per
share exercise price equal to the closing price of the Companys common stock on October 2, 2006
(the first trading day after the completion of the Acquisition). The options vest ratably over a
term of four years and have a term of ten years. Each of the principal owners of the MDHC
Companies is subject to a five-year non-competition covenant following the closing of the
Acquisition.
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Unless otherwise indicated or the context otherwise requires, all references in this Form 10-Q
to we, us, our, Continucare or the Company refers to Continucare Corporation and its
consolidated subsidiaries. All references to the MDHC Companies refer to Miami Dade Health
Centers, Inc. and its affiliated companies.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
We caution our investors that certain important factors may affect our actual results and
could cause such results to differ materially from any forward-looking statement which may have
been deemed to have been made in this report or which are otherwise made by us or on our behalf.
For this purpose, any statements contained in this report that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting the generality of the
foregoing, words such as may, will, expect, believe, anticipate, intend, plan,
predict, should, potential, could, would, estimate, continue or pursue, or the
negative other variations thereof or comparable terminology are intended to identify
forward-looking statements. Such statements include, but are not limited to the following:
|
|
|
Our ability to make capital expenditures and respond to capital needs; |
|
|
|
|
Our ability to enhance the services we provide to our patients; |
|
|
|
|
Our ability to strengthen our medical management capabilities; |
|
|
|
|
Our ability to improve our physician network; |
|
|
|
|
Our ability to enter into or renew our managed care agreements and negotiate terms
which are favorable to us and affiliated physicians; |
|
|
|
|
The estimated increase in our intangible assets as a result of our acquisition of
the MDHC Companies, and its impact on us; |
|
|
|
|
Our ability to respond to future changes in Medicare reimbursement levels and
reimbursement rates from other third parties; |
|
|
|
|
Our compliance with applicable laws and regulations; |
|
|
|
|
Our ability to establish relationships and expand into new geographic markets; |
|
|
|
|
Our ability to expand our network through additional medical centers or other facilities; |
|
|
|
|
The potential impact on our claims loss ratio as a result of the Medicare Risk
Adjustments (MRA), the Medicare Prescription Drug, Improvement and Modernization Act
of 2003 (the Medicare Modernization Act) and the enhanced benefits our HMO affiliates
offer under their Medicare Advantage Plans; |
|
|
|
|
Changes in the component of our medical claims expense attributable to the Medicare
Prescription Drug program; |
|
|
|
|
The ability of our stop-loss insurance coverage to limit the financial risk to us of
our risk arrangements with the health maintenance organizations (HMOs); |
|
|
|
|
The application and impact of Statement of Financial Accounting Standards No. 123(R)
(SFAS 123(R)) on our future results of operations; |
|
|
|
|
Our ability to utilize our net operating losses for Federal income tax purposes; |
|
|
|
|
The impact of the newly effective Medicare prescription drug plan on our results of operations; and |
|
|
|
|
Our intent to repurchase our common stock under our stock repurchase program. |
12
Forward-looking statements involve risks and uncertainties that cannot be predicted or
quantified and, consequently, actual results may differ materially from those expressed or implied
by such forward-looking statements. Such risks and uncertainties include, but are not limited to
the following:
|
|
|
Our dependence on two HMOs for substantially all of our revenues; |
|
|
|
|
Our ability to respond to capital needs; |
|
|
|
|
Our ability to achieve expected levels of patient volumes and control the costs of
providing services; |
|
|
|
|
Pricing pressures exerted on us by managed care organizations; |
|
|
|
|
The level of payments we receive from governmental programs and other third party payors; |
|
|
|
|
Our and our HMO affiliates ability to improve efficiencies in utilization with
respect to the Medicare Prescription Drug program; |
|
|
|
|
Our ability to rapidly integrate the MDHC Companies operations and personnel; |
|
|
|
|
The realization of the expected synergies and benefits of the proposed acquisition; |
|
|
|
|
Our ability to comply with Section 404 of the Sarbanes-Oxley Act of 2002; |
|
|
|
|
Our ability to serve a significantly larger patient base; |
|
|
|
|
Trends in patient enrollment; |
|
|
|
|
Our ability to successfully recruit and retain qualified medical professionals; |
|
|
|
|
Future legislative or regulatory changes, including possible changes in Medicare and
Medicaid programs that may impact reimbursements to health care providers and insurers
or the benefits we expect to realize from our acquisition of the MDHC Companies; |
|
|
|
|
Our ability to comply with applicable laws and regulations; |
|
|
|
|
The impact of the Medicare Modernization Act and MRA on payments we receive for our
respective managed care operations; including the risk that any additional premiums we
may receive as a result of the newly effective Medicare prescription drug plan will not
be sufficient to compensate us for the expenses that we incur as a result of that plan; |
|
|
|
|
Technological and pharmaceutical improvements that increase the cost of providing,
or reduce the demand for, health care; |
|
|
|
|
Changes in our revenue mix and claims loss ratio; |
|
|
|
|
Changes in the range of medical services we or the MDHC Companies provide or for
which our HMO affiliates offer coverage; |
|
|
|
|
Our ability to enter into and renew managed care provider agreements on acceptable terms; |
|
|
|
|
Loss of significant contracts with HMOs; |
|
|
|
|
The ability of our compliance program to detect and prevent regulatory compliance problems; |
|
|
|
|
Delays in receiving payments; |
|
|
|
|
Increases in the cost of insurance coverage, including our stop-loss coverage, or
the loss of insurance coverage; |
|
|
|
|
The collectibility of our uninsured accounts and deductible and co-pay amounts; |
|
|
|
|
Federal and state investigations; |
|
|
|
|
Lawsuits for medical malpractice and the outcome of any such litigation; |
|
|
|
|
Our estimate of the proportion of our total assets comprised by intangible assets
immediately following our acquisition of the MDHC Companies (the Acquistion); |
|
|
|
|
Changes in estimates and judgments associated with our critical accounting policies; |
|
|
|
|
Our dependence on our information processing systems and the management information
systems of our HMO affiliates; |
|
|
|
|
Impairment charges that could be required in future periods; |
|
|
|
|
The impact on our liquidity of any repurchases of our common stock that we may effect; |
|
|
|
|
The inherent uncertainty in financial forecasts which are based upon assumptions
which may prove incorrect or inaccurate; |
|
|
|
|
General economic conditions; and |
|
|
|
|
Uncertainties generally associated with the health care business. |
13
We assume no responsibility to update our forward-looking statements as a result of new
information, future events or otherwise. Additional information concerning these and other risks
and uncertainties is contained in our filings with the Securities and Exchange Commission,
including the section entitled Risk Factors in our Annual Report on Form 10-K for Fiscal 2006 and
in Item 1A of Part Two of this
Form 10-Q.
General
We are a provider of primary care physician services. Through our network of 20 medical
centers, we provide primary care medical services on an outpatient basis. We also provide practice
management services to 15 IPAs. All of our medical centers and IPAs are located in Miami-Dade,
Broward and Hillsborough Counties, Florida. As of September 30, 2006, we provided services to or
for approximately 15,500 patients on a risk basis and approximately 8,600 patients on a non-risk
basis and as a result of our acquisition of the MDHC Companies, we increased our patient population
by approximately 12,900 full risk patients and approximately 4,700 limited risk or non-risk
patients. For the three-months ended September 30, 2006, approximately 95% of our revenue was
generated by providing services to Medicare-eligible members under risk arrangements that require
us to assume responsibility to provide and pay for all of our patients medical needs in exchange
for a capitated fee, typically a percentage of the premium received by an HMO from various payor
sources.
Effective January 1, 2006, we entered into an Independent Practice Association Participation
Agreement (the Risk IPA Agreement) with Humana under which we agreed to assume certain management
responsibilities on a risk basis for Humanas Medicare and Medicaid members assigned to certain
IPAs practicing in Miami-Dade and Broward Counties, Florida. Under the Risk IPA Agreement, we
receive a capitation fee established as a percentage of premium that Humana receives for its
members who have selected the IPAs as their primary care physicians and assume responsibility for
the cost of substantially all medical services provided to these members, even those we do not
provide directly. During the three-month period ended September 30, 2006, medical service revenue
and medical services expenses related to the Risk IPA Agreement approximated $4.0 million and $3.6
million, respectively. As of September 30, 2006, the IPAs provided services to or for
approximately 2,100 Medicare and Medicaid patients enrolled in Humana managed care plans. The Risk
IPA Agreement replaces the Physician Group Participation Agreement with Humana (the Humana PGP
Agreement) that was terminated effective December 31, 2005. Under the Humana PGP Agreement, we
assumed certain management responsibilities on a non-risk basis for Humanas Medicare, Medicaid and
commercial members assigned to selected primary care physicians in Miami-Dade and Broward Counties,
Florida. Revenue from this contract consisted of a monthly management fee intended to cover the
costs of providing these services and amounted to approximately $0.1 million during the three-month
period ended September 30, 2005.
Medicare Considerations
Substantially all of our net medical services revenue from continuing operations is based upon
Medicare funded programs. The federal government from time to time explores ways to reduce medical
care costs through Medicare reform and through health care reform generally. Any changes that
would limit, reduce or delay receipt of Medicare funding or any developments that would disqualify
us from receiving Medicare funding could have a material adverse effect on our business, results of
operations, prospects, financial results, financial condition or cash flows. Due to the diverse
range of proposals put forth and the uncertainty of any proposals adoption, we cannot predict what
impact any Medicare reform proposal ultimately adopted may have on our business, financial position
or results of operations.
On January 1, 2006, the Medicare Prescription Drug Plan created by the Medicare Modernization
Act became effective. As a result, our HMO affiliates have established or expanded prescription
drug benefit plans for their Medicare Advantage members. Under the terms of our risk arrangements,
we are financially responsible for a substantial portion of the cost of the prescription drugs our
patients receive, and, in exchange, our HMO affiliates have agreed to provide us with an additional
per member capitated fee related to prescription drug coverage. However, there can be no assurance
that the additional fee that we receive will be sufficient to reimburse us for the additional costs
that we may incur under the new Medicare Prescription Drug Plan.
14
In addition, the premiums our HMO affiliates receive from the Centers for Medicare and
Medicaid Services (CMS) for their Medicare Prescription Drug Plans is subject to periodic
adjustment, positive or negative, based upon the application of risk corridors that compare their
plans revenues targeted in their bids to actual prescription drug costs. Variances exceeding
certain thresholds may result in CMS making additional payments to the HMOs or require the HMOs to
refund to CMS a portion of the payments they received. Our HMO affiliates estimate and
periodically adjust premium revenues related to the risk corridor payment adjustment, and a portion
of the HMOs estimated premium revenue adjustment is allocated to us. As a result, revenue
recognized under our risk arrangements with our HMO affiliates are net of the portion of the
estimated risk corridor adjustment allocated to us. The portion of any such risk corridor
adjustment that the HMOs allocate to us may not directly correlate to the historical utilization
patterns of our patients or the costs that we may incur in future periods. During the three-month
period ended September 30, 2006, one of our HMO affiliates allocated to us an adjustment related to
their risk corridor payment which had the effect of reducing our operating income by approximately
$1.3 million. No amount was recorded during the three-month period ended September 30, 2005 as the
Medicare Prescription Drug Plan program was not then effective.
The Medicare Prescription Drug Plan has also been subject to significant public criticism and
controversy, and members of Congress have discussed possible changes to the program as well as ways
to reduce the programs cost to the federal government. We cannot predict what impact, if any,
these developments may have on the Medicare Prescription Drug Plan or on our future financial
results.
Critical Accounting Policies and Estimates
Our significant accounting policies are described in Note 2 to the consolidated financial
statements included in our Annual Report on Form 10-K for Fiscal 2006. Included within these
policies are certain policies which contain critical accounting estimates and, therefore, have been
deemed to be critical accounting policies. Critical accounting estimates are those which require
management to make assumptions about matters that were uncertain at the time the estimate was made
and for which the use of different estimates, which reasonably could have been used, or changes in
the accounting estimates that are reasonably likely to occur from period to period, could have a
material impact on the presentation of our financial condition, changes in financial condition or
results of operations.
We base our estimates and assumptions on historical experience, knowledge of current events
and anticipated future events, and we continuously evaluate and update our estimates and
assumptions. However, our estimates and assumptions may ultimately prove to be incorrect or
incomplete and our actual results may differ materially. We believe the following critical
accounting policies involve the most significant judgments and estimates used in the preparation of
our consolidated financial statements.
Revenue Recognition
Under our risk contracts with HMOs, we receive a percentage of premium or other capitated fee
for each patient that chooses one of our physicians as their primary care physician. Revenue under
these agreements is generally recorded in the period we assume responsibility to provide services
at the rates then in effect as determined by the respective contract. As part of the Medicare
Advantage program, the CMS periodically recomputes the premiums to be paid to the HMOs based on
updated health status of participants and updated demographic factors. We record any adjustments
to this revenue at the time that the information necessary to make the determination of the
adjustment is received from the HMO or CMS.
Under our risk agreements, we assume responsibility for the cost of all medical services
provided to the patient, even those we do not provide directly, in exchange for a percentage of
premium or other capitated fee. To the extent that patients require more frequent or expensive
care, our revenue under a contract may be insufficient to cover the costs of care provided. When
it is probable that expected future health care costs and maintenance costs under a contract or
group of existing contracts will exceed anticipated capitated revenue on those contracts, we
recognize losses on our prepaid health care services with HMOs. No contracts were considered loss
contracts at
15
September 30, 2006 because we have the right to terminate unprofitable physicians and close
unprofitable centers under our managed care contracts.
Under our limited risk and non-risk contracts with HMOs, we receive a capitation fee based on
the number of patients for which we are providing services on a monthly basis. The capitation fee
is recorded as revenue in the period in which services are provided as determined by the respective
contract.
Payments under both our risk contracts and our non-risk contracts (for both the Medicare
Advantange program as well as Medicaid) are also subject to reconciliation based upon historical
patient enrollment data. We record any adjustments to this revenue at the time that the
information necessary to make the determination of the adjustment is received from the HMO or the
applicable governmental body.
Medical Claims Expense Recognition
The cost of health care services provided or contracted for is accrued in the period in which
the services are provided. This cost includes our estimate of the related liability for medical
claims incurred in the period but not yet reported, or IBNR. IBNR represents a material portion of
our medical claims liability which is presented in the balance sheet net of amounts due from HMOs.
Changes in this estimate can materially affect, either favorably or unfavorably, our results from
operations and overall financial position.
We develop our estimate of IBNR primarily based on historical claims incurred per member per
month. We adjust our estimate if we have unusually high or low utilization or if benefit changes
provided under the HMO plans are expected to significantly increase or reduce our claims exposure.
We also adjust our estimate for differences between the estimated claims expense recorded in prior
months to actual claims expense as claims are paid by the HMO and reported to us.
To further corroborate our estimate of medical claims, an independent actuarial calculation is
performed for us on a quarterly basis. This independent actuarial calculation indicates that IBNR
as of September 30, 2006 was between approximately $12.1 million and $13.8 million. Based on our
internal analysis and the independent actuarial calculation, as of September 30, 2006, we recorded
a liability of approximately $12.7 million for IBNR. The decrease in the liability for IBNR of
$1.5 million or 10.7% to $12.7 million as of September 30, 2006 from $14.2 million as of June 30,
2006 was primarily due to the timing of claims paid by one of our HMOs. The liability for IBNR
remained relatively unchanged at $11.6 million and $11.7 million as of September 30, 2005 and June
30, 2005, respectively.
Consideration of Impairment Related to Goodwill and Other Intangible Assets
Our balance sheet includes intangible assets, including goodwill and other separately
identifiable intangible assets, which represented approximately 38% of our total assets at
September 30, 2006. As a result of the Acquisition, the percentage of our total consolidated
assets represented by intangible assets increased. Based on preliminary financial data of the MDHC
Companies as of September 30, 2006, we believe that, as of the closing of the Acquisition, our
intangible assets represented at least approximately 60% of our total assets as of that date.
Under Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible
Assets, goodwill and intangible assets with indefinite useful lives are no longer amortized, but
are reviewed for impairment on an annual basis or more frequently if certain indicators of
permanent impairment arise. Intangible assets with definite useful lives are amortized over their
respective useful lives to their estimated residual values and also reviewed for impairment
annually, or more frequently if certain indicators of permanent impairment arise. Indicators of a
permanent impairment include, among other things, a significant adverse change in legal factors or
the business climate, the loss of a key HMO contract, an adverse action by a regulator,
unanticipated competition, and the loss of key personnel or allocation of goodwill to a portion of
business that is to be sold.
Because we operate in a single segment of business, we have determined that we have a single
reporting unit and we perform our impairment test for goodwill on an enterprise level. In
performing the impairment test, we compare the total current market value of all of our outstanding
common stock, to the current carrying value of our
16
total net assets, including goodwill and intangible assets. Depending on the market value of
our common stock at the time that an impairment test is required, there is a risk that a portion of
our intangible assets would be considered impaired and must be written-off during that period. We
completed our annual impairment test on May 1, 2006, and determined that no indicators of
impairment existed. In addition, no indicators of impairment were noted for the three-month period
ended September 30, 2006 and, accordingly, no impairment charges were recognized. Should we later
determine that an indicator of impairment exists, we would be required to perform an additional
impairment test.
Realization of Deferred Tax Assets
We account for income taxes in accordance with SFAS No. 109, Accounting for Income Taxes
(SFAS 109) which requires that deferred tax assets and liabilities be recognized using enacted
tax rates for the effect of temporary differences between the book and tax bases of recorded assets
and liabilities. SFAS No. 109 also requires that deferred tax assets be reduced by a valuation
allowance if it is more likely than not that some portion or all of the deferred tax asset will not
be realized.
As part of the process of preparing our consolidated financial statements, we estimate our
income taxes based on our actual current tax exposure together with assessing temporary differences
resulting from differing treatment of items for tax and accounting purposes. We also recognize as
deferred tax assets the future tax benefits from net operating loss carryforwards. We evaluate the
realizability of these deferred tax assets by assessing their valuation allowances and by adjusting
the amount of such allowances, if necessary. Among the factors used to assess the likelihood of
realization are our projections of future taxable income streams, the expected timing of the
reversals of existing temporary differences, and the impact of tax planning strategies that could
be implemented to avoid the potential loss of future tax benefits. However, changes in tax codes,
statutory tax rates or future taxable income levels could materially impact our valuation of tax
accruals and assets and could cause our provision for income taxes to vary significantly from
period to period.
At September 30, 2006, we had deferred tax assets in excess of deferred tax liabilities of
approximately $3.9 million. During the three-month period ended September 30, 2006, we determined
that it is more likely than not that those assets will be realized (although realization is not
assured), resulting in no valuation allowance at September 30, 2006.
Stock-Based Compensation Expense
Effective July 1, 2005, we adopted SFAS 123(R) using the modified prospective transition
method. Prior to the adoption of SFAS 123(R) we followed Accounting Principles Board Opinion No.
25, (APB No. 25), Accounting for Stock Issued to Employees, and related Interpretations in
accounting for its employee stock options. For the three-month periods ended September 30, 2006
and 2005, the adoption of SFAS No. 123(R) had no effect on cash flow from operations and
approximately $0.1 million and $0, respectively, on cash flow from financing activities.
SFAS 123(R) requires us to recognize compensation costs related to our share-based payment
transactions with employees in our financial statements. SFAS 123(R) requires us to calculate this
cost based on the grant date fair value of the equity instrument. As a result of adopting SFAS No.
123(R) on July 1, 2005, for the three-month periods ended September 30, 2006 and 2005, we
recognized share-based compensation expense of $0.3 million and $0.2 million, respectively. As of
September 30, 2006, there was $1.6 million of total unrecognized compensation cost related to
non-vested stock options, which is expected to be recognized over a weighted-average period of 2.2
years.
Consistent with our practices prior to adopting SFAS 123(R), we have elected to calculate the
fair value of our employee stock options using the Black-Scholes option pricing model. Using this
model we calculated the fair value for employee stock options granted during the three-month
periods ended September 30, 2006 and 2005 based on the following assumptions: risk-free interest
rate ranging from 5.08% to 5.16% and 4.21% to 4.35%, respectively; dividend yield of 0%;
weighted-average volatility factor of the expected market price of our common stock of 64.9% and
74.8%, respectively, and weighted-average expected life of the options ranging from 3 to 6 years
depending on
17
the vesting provisions of each option. The expected life of the options is based on the historical
exercise behavior of our employees. The expected volatility factor is based on the historical
volatility of the market price of our common stock as adjusted for certain events that management
deemed to be non-recurring and non-indicative of future events.
SFAS 123(R) does not require the use of any particular option valuation model. Because our
stock options have characteristics significantly different from traded options and because changes
in the subjective input assumptions can materially affect the fair value estimate, in managements
opinion, it is possible that existing models may not necessarily provide a reliable measure of the
fair value of our employee stock options. We selected the Black-Scholes model based on our prior
experience with it, its wide use by issuers comparable to us, and our review of alternate option
valuation models. Based on these factors, we believe that the Black-Scholes model and the
assumptions we made in applying it provide a reasonable estimate of the fair value of our employee
stock options.
The effect of applying the fair value method of accounting for stock options on reported net
income for any period may not be representative of the effects for future periods because our
outstanding options typically vest over a period of several years and additional awards may be made
in future periods.
RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with the unaudited
condensed consolidated financial statements and notes thereto appearing elsewhere in this Form
10-Q.
COMPARISON OF THE THREE-MONTH PERIOD ENDED SEPTEMBER 30, 2006 TO THE THREE-MONTH PERIOD ENDED
SEPTEMBER 30, 2005
Revenue
Medical services revenue increased by $6.2 million, or 20.7%, to $35.9 million for the
three-month period ended September 30, 2006 from $29.7 million for the three-month period ended
September 30, 2005 due primarily to increases in our Medicare revenue.
The most significant component of our medical services revenue is the revenue we generate from
Medicare patients under risk arrangements which increased by $5.4 million or 19.0%, during the
three-month period ended September 30, 2006. During the three-month period ended September 30,
2006, revenue generated by our Medicare risk arrangements increased approximately 8.8% on a per
patient per month basis and Medicare patient months increased by approximately 9.3% over the
comparable period of Fiscal 2006. The increase in Medicare revenue was primarily due to revenue
associated with the IPAs that were converted from a non-risk arrangement to a risk arrangement
effective January 1, 2006, higher per patient per month premiums and the increased phase-in of the
Medicare risk adjustment program. Under the Medicare risk adjustment program, the health status
and demographic factors of Medicare Advantage participants are taken into account in determining
premiums paid for each participant. CMS periodically recomputes the premiums to be paid to the
HMOs based on updated health status, demographic factors and, in the case of Medicare Prescription
Drug Plan benefits, CMSs risk corridor adjustment methodology. Medicare risk adjustments recorded
during each of the three-month periods ended September 30, 2006 and 2005 resulted in increases to
our medical services revenue of approximately $0.6 million. Future Medicare risk adjustments may
result in reductions of revenue depending on the future health status and demographic factors of
our patients as well as the application of CMSs risk corridor methodology to the HMOs Medicare
Prescription Drug Programs. The increase in Medicare patient months was primarily due to the
conversion of the IPAs from a non-risk arrangement to a risk arrangement effective January 1, 2006.
Management fee revenue and other income of $0.1 million for the three-month period ended
September 30, 2005 related primarily to revenue generated under our limited risk and non-risk
contracts with Humana under the PGP Agreement.
Revenue generated by our managed care entities under contracts with Humana accounted for
approximately 80% and 78% of our medical services revenue for the three-month periods ended
September 30, 2006 and 2005,
18
respectively. Revenue generated by our managed care entities under contracts with Vista accounted
for approximately 19% and 21% of our medical services revenue for the three-month periods ended
September 30, 2006 and 2005, respectively.
Operating Expenses
Medical services expenses are comprised of medical claims expense and other direct costs
related to the provision of medical services to our patients including a portion of our stock-based
compensation expense. Because our risk contracts with HMOs provide that we are financially
responsible for the cost of substantially all medical services provided to our patients under those
contracts, our medical claims expense includes the costs of prescription drugs our patients receive
as well as medical services provided to patients under our risk contracts by providers other than
us. Other direct costs include the salaries, taxes and benefits of our health professionals
providing primary care services, medical malpractice insurance costs, capitation payments to our
IPA physicians and other costs related to the provision of medical services to our patients.
Medical services expenses for the three-month period ended September 30, 2006 increased by
$5.9 million, or 23.8%, to $30.4 million from $24.5 million for the three-month period ended
September 30, 2005. This increase is primarily due to an increase in medical claims expense which
is the largest component of medical services expense. Medical claims expense increased by $5.7
million, or 26.4%, to $27.1 million for the three-month period ended September 30, 2006 from $21.4
million for the three-month period ended September 30, 2005 primarily as a result of a 12.7%
increase on a per patient per month basis in medical claims expenses related to our Medicare
patients and a 9.3% increase in Medicare patient months. The increase in Medicare per patient per
month medical claims expense is primarily attributable to enhanced benefits offered by our HMO
affiliates and inflationary trends in the health care industry. The increase in Medicare patient
months is primarily attributable to the conversion of the IPAs to a risk arrangement effective
January 1, 2006. In addition, our pharmacy expense related to one of our HMO affiliates for the
first quarter of Fiscal 2007 increased by approximately $0.3 million, or approximately 31%, over
the three months ended June 30, 2006. We believe that a significant portion of this increase was
attributable to one of our HMO affiliates transferring a portion of their pharmacy fulfillment
services for our full risk patients to a different pharmacy benefit manager. We believe it may be
possible to recover a significant portion of the increase, but there can be no assurance that we
will be successful in doing so. We and our HMO affiliate are also seeking to reduce our pharmacy
expense and, if we are successful in doing so, we expect that our pharmacy expense will decline to
levels experienced under the former pharmacy benefit manager.
Medical services expenses increased to 84.5% of total revenue for the three-month period ended
September 30, 2006 as compared to 82.1% for the three-month period ended September 30, 2005. Our
claims loss ratio (medical claims expense as a percentage of medical services revenue) increased to
75.4% for the three-month ended September 30, 2006 from 72.0% for the three-month period ended
September 30, 2005. These increases were primarily due to the higher historical claims loss ratio
experienced by the IPAs that were converted from a non-risk arrangement to a risk arrangement
effective January 1, 2006 and due to the enhanced benefits offered by our HMO affiliates to
Medicare patients for calendar 2006. HMOs are under continuous competitive pressure to enhance the
benefits they offer to their members. However, the premiums CMS pays to HMOs for Medicare
Advantage members are generally not increased as a result of those benefit enhancements. As a
result, we expect HMOs will be under continuing competitive pressure to offer more, and possibly
more expensive, benefits to their Medicare Advantage members in exchange for the same premium.
This may result in an increase in our claims loss ratio in future periods, which could reduce our
profitability and cash flows. In addition, the IPAs converted to a risk arrangement have
historically experienced a higher claims loss ratio than our other operations. While we will seek
to reduce the claims loss ratio of those IPAs to a level comparable to that of our other
operations, there can be no assurance that we will be successful in doing so. If we are not
successful in reducing the claims loss ratio of those IPAs, our profitability and cash flows may be
adversely affected. However, we cannot quantify what impact, if any, these developments may have
on our claims loss ratio (which fluctuates from period to period) or results of operations in
future periods.
Other direct costs increased by $0.2 million, or 5.7%, to $3.3 million for the three-month
period ended September 30, 2006 from $3.1 million for the three-month period ended September 30,
2005. As a percentage of
19
total revenue, other direct costs decreased to 9.2% for the three-month period ended September 30,
2006 from 10.5% for the three-month period ended September 30, 2005. The increase in the amount of
other direct costs was primarily due to an increase in capitation fees paid to the IPAs.
Administrative payroll and employee benefits expense increased by $0.2 million, or 16.5%, to
$1.6 million for the three-month period ended September 30, 2006 from $1.4 million for the
three-month period ended September 30, 2005. As a percentage of total revenue, administrative
payroll and employee benefits expense decreased to 4.5% for the three-month period ended September
30, 2005 from 4.7% for the three-month period ended September 30, 2005. The increase in
administrative payroll and employee benefits expense was primarily due to an increase in
stock-based compensation expense and an increase in personnel.
General and administrative expenses increased by $0.1 million or 7.9%, to $1.8 million for the
three-month period ended September 30, 2006 from $1.7 million for the three-month period ended
September 30, 2005. As a percentage of total revenue, general and administrative expenses
decreased to 5.1% for the three-month period ended September 30, 2006 from 5.7% for the three-month
period ended September 30, 2005. The increase in general and administrative expenses was primarily
due to an increase in professional fees and a loss on disposal of fixed assets.
Income from Operations
Income from operations for the three-month period ended September 30, 2006 decreased by $0.1
million to $2.1 million from $2.2 million for the three-month period ended September 30, 2005.
Interest Income
Interest income increased by $0.1 million, or 160.6%, to $0.2 million for the three-month
period ended September 30, 2006 from $0.1 million for the three-month period ended September 30,
2005. The increase in interest income was primarily due to an increase in cash and cash
equivalents and an increase in interest rates earned on such investments.
Taxes
An income tax provision of $0.8 million was recorded for the three-month periods ended
September 30, 2006 and 2005.
Net Income
Net income for the three-month periods ended September 30, 2006 and 2005 remained relatively
unchanged at $1.4 million.
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2006, working capital was $17.9 million, an increase of $2.3 million from
$15.6 million at June 30, 2006. The increase in working capital for the three-month period ended
September 30, 2006 was primarily due to income before income tax provision of $2.3 million. Cash
and cash equivalents were $12.0 million at September 30, 2006 compared to $10.7 million at June 30,
2006.
Net cash of $1.7 million was provided by operating activities from continuing operations for
the three-month period ended September 30, 2006 compared to $0.2 million for the three-month period
ended September 30, 2005. The $1.5 million increase in cash provided by operating activities for
the three-month period ended September 30, 2006 compared to the three-month period ended September
30, 2005 was primarily due to a decrease in amounts due from HMOs of $2.1 million.
Net cash of approximately $0.5 million was used for investing activities for the three-month
period ended September 30, 2006 compared to approximately $38,000 for the three-month period ended
September 30, 2005.
20
The $0.5 million increase in net cash used for investing activities primarily related to the
purchase of equipment and increase in other assets related to capitalized acquisition costs.
Net
cash of approximately $0.1 million was provided by financing activities for the three-month
period ended September 30, 2006 compared to net cash used of $0.6 million for the three-month
period ended September 30, 2005. The $0.7 million decrease in cash used in financing activities
for the three-month period ended September 30, 2006 was primarily due to a $0.7 million decrease of
in cash used for the repurchase of common stock.
Pursuant to the terms under our managed care agreements with certain of our HMO affiliates, we
posted irrevocable standby letters of credit amounting to $1.1 million to secure our payment
obligations to those HMOs. We are required to maintain these letters of credit throughout the term
of the managed care agreements.
In May 2005, our Board of Directors increased our previously announced program to repurchase
shares of our common stock to a total of 2,500,000 shares. Any such repurchases will be made from
time to time at the discretion of our management in the open market or in privately negotiated
transactions subject to market conditions and other factors. We anticipate that any such
repurchases of shares will be funded through cash from operations. As of November 2, 2006, we had
repurchased 1,157,467 shares of our common stock for approximately $3.0 million.
Effective October 1, 2006, we completed the Acquisition. In connection with the completion of
the Acquisition and in consideration for the assets acquired pursuant to the Acquisition, we paid
the MDHC Companies approximately $5.0 million in cash, issued to the MDHC Companies 20.0 million
shares of our common stock and assumed or repaid certain indebtedness and liabilities of the MDHC
Companies, and, in November 2006, 248,661 of such shares were cancelled in connection with a
post-closing purchase price adjustment. Pursuant to the terms of the Acquisition, we are also
obligated to pay the principal owners of the MDHC Companies an additional $1.0 million in cash on
October 1, 2007, the first anniversary date of the closing, and up to $2.0 million in cash based on
the working capital of the MDHC Companies as of October 1, 2006 and the monthly payments in respect
of the MDHC Companies business operations received by us or any of our subsidiaries from certain
identified third-party payors during the fourteen day period commencing on October 1, 2006. We
will also make certain other payments to the principal owners of the MDHC Companies depending on
the collection of certain receivables that were fully reserved on the books of the MDHC Companies
as of December 31, 2005.
On September 26, 2006, we entered into two term loan facilities funded out of lines of credit
(the Term Loans) with maximum loan amounts of $4.8 million and $1.0 million, respectively. Each
of the Term Loans requires us to make mandatory monthly payments that reduce the lines of credit
under the Term Loans. Subject to the terms and conditions of the Term Loans, any prepayments made
to the Term Loans by us may be re-borrowed by us on a revolving basis so long as the line of credit
applicable to such Term Loan, as reduced by the mandatory monthly payment, is not exceeded. Each
of the Term Loans (a) matures on October 1, 2011, (b) has variable interest rates at a per annum
rate equal to the sum of 2.4% and the One-Month LIBOR rate, (c) requires us, on a consolidated
basis, to maintain a tangible net worth of $12.0 million and a debt coverage ratio of 1.25 to 1 and
(d) are secured by substantially all of our assets, including those assets acquired pursuant to the
Acquisition. Effective October 1, 2006, we fully drew on these Term Loans to fund certain portions
of the cash payable upon the closing of the Acquisition.
Also effective September 26, 2006, we amended the terms of our existing $5,000,000 Credit
Facility to eliminate the financial covenant which previously required our EBITDA to exceed
$1,500,000 on a trailing 12-month basis any time during which amounts are outstanding under the
Credit Facility and replace such covenant with covenants requiring us, on a consolidated business,
to maintain a tangible net worth of $12.0 million and a debt coverage ratio of 1.25 to 1.
Effective October 1, 2006, we drew approximately $1.8 million under the Credit Facility to fund
portions of the cash payable upon the closing of the Acquisition.
As a result of the Acquisition, the consolidated net indebtedness of the Company increased by
approximately, $7.6 million. However, since the closing of the Acquisition, the Company has repaid
substantially all of that increased indebtedness, and such amounts are now available for future
borrowing.
21
We believe that we will be able to fund our capital commitments, our anticipated operating
cash requirements for the foreseeable future and satisfy any remaining obligations from our working
capital, anticipated cash flows from operations, our Credit Facility, and our Term Loans.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
At September 30, 2006, we had only certificates of deposit and cash equivalents invested in
high grade, short-term securities, which are not typically subject to material market risk. At
September 30, 2006, we had capital lease obligations outstanding at fixed rates. For loans with
fixed interest rates, a hypothetical 10% change in interest rates would have no impact on our
future earnings and cash flows related to these instruments and would have an immaterial impact on
the fair value of these instruments. Our Term Loans and Credit Facility are interest rate
sensitive, however, we had no amount outstanding under these facilities at September 30, 2006. We
have no material risk associated with foreign currency exchange rates or commodity prices.
ITEM 4. CONTROLS AND PROCEDURES
Our management, with the participation of our Chief Executive Officer and Chief Financial
Officer, have evaluated the effectiveness of our disclosure controls and procedures as of the end
of the period covered by this report. Based on that evaluation, the Chief Executive Officer and
Chief Financial Officer have concluded that the disclosure controls and procedures are effective.
However, that conclusion should be considered in light of the various limitations described below
on the effectiveness of those controls and procedures, some of which pertain to most if not all
business enterprises, and some of which arise as a result of the nature of our business. Our
management, including our Chief Executive Officer and our Chief Financial Officer, does not expect
that our disclosure controls and procedures will prevent all errors and all improper conduct. A
control system, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. Further, the design of a
control system must reflect the fact that there are resource constraints, and the benefits of
controls must be considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of improper conduct, if any, have been detected. These inherent limitations include
the realities that judgments in decision-making can be faulty, and that breakdowns can occur
because of simple error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people, or by management override of the control.
Further, the design of any system of controls also is based in part upon assumptions about the
likelihood of future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions; over time, controls may become
inadequate because of changes in conditions, or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a cost-effective control
system, misstatements due to error or fraud may occur and not be detected. In addition, we depend
on our HMO affiliates for certain financial and other information that we receive concerning the
medical services revenue and expenses that we earn and incur. Because our HMO affiliates generate
that information for us we have less control over the manner in which that information is
generated. In addition, because the Acquisition was not completed until after the conclusion of
the quarterly period to which this report on Form 10-Q relates, our managements assessment of our
disclosure controls and procedures as of September 30, 2006, did not cover the disclosure controls
and procedures of the MDHC Companies. However, because we did not complete the acquisition until
after the conclusion of the quarterly period to which this report on Form 10-Q relates, the MDHC
companies were not significant to the information contained in this Form 10-Q. There were no
changes in our internal controls or other factors during the first quarter of our fiscal year, nor
were there any corrective actions required with regard to significant deficiencies and material
weaknesses.
Provided with this quarterly report on Form 10-Q are certifications of our Chief Executive
Officer and our Chief Financial Officer. We are required to provide those certifications by Section
302 of the Sarbanes-Oxley Act of 2002 and the Securities and Exchange Commissions implementing
regulations. Item 4 of this quarterly report on Form 10-Q is the information concerning the
evaluation referred to in those certifications, and you should read this information in conjunction
with those certifications for a more complete understanding of the topics presented.
22
PART II OTHER INFORMATION
Item 1. Legal Proceedings
See Note 8 of our Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in our Form 10-K
for Fiscal 2006 and in other reports filed from time to time with the SEC since the date we filed
our Form 10-K. Readers are urged to carefully review our risk factors since they may cause our
results to differ from the forward-looking statements made in this report or otherwise made by or
on our behalf. Those risk factors are not the only ones we face. If any of these risks actually
occurs, our business, financial condition and results of operations would suffer. Additional risks
not presently known to us or other factors not perceived by us to present significant risks to our
business at this time also may impair our business operation. We do not undertake to update any of
these forward-looking statements or to announce the results of any revisions to these
forward-looking statements except as required by law.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In May 2005, we announced that we had increased our previously announced stock
repurchase program to authorize the buy back of up to 2,500,000 shares of our common stock. Any
such repurchases will be made from time to time at the discretion of our management in the open
market or in privately negotiated transactions subject to market conditions and other factors. We
anticipate that any such repurchases of shares will be funded through cash from operations. There
is no expiration date specified for this program. The following table provides information with
respect to our stock repurchases during the first quarter of Fiscal 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number of |
|
Maximum Number of |
|
|
|
|
|
|
|
|
|
|
Shares Purchased as |
|
Shares that May Yet |
|
|
Total Number of |
|
Average Price Paid |
|
Part of Publicly |
|
Be Purchased Under |
Period |
|
Shares Purchased |
|
per Share |
|
Announced Plan |
|
the Plan |
July 1 to July 31, 2006 |
|
|
- |
|
|
|
N/A |
|
|
|
- |
|
|
|
1,342,533 |
|
August 1 to August 31, 2006 |
|
|
- |
|
|
|
N/A |
|
|
|
- |
|
|
|
1,342,533 |
|
September 1 to September
30, 2006 |
|
|
- |
|
|
|
N/A |
|
|
|
- |
|
|
|
1,342,533 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals |
|
|
- |
|
|
|
N/A |
|
|
|
- |
|
|
|
|
|
Item 3. Defaults Upon Senior Securities
Not Applicable
Item 4. Submission of Matters to a Vote of Security Holders
At a Special Meeting of Shareholders held on September 19, 2006, our shareholders voted to
approve the issuance of 20.0 million shares of our common stock pursuant to an asset purchase
agreement between, among others, Continucare and the MDHC Companies. The number of votes cast for,
against or abstain with respect to this proposal were as follows:
|
|
|
|
|
For
|
|
Against
|
|
Abstain |
|
|
|
|
|
33,815,376
|
|
118,650
|
|
39,745 |
Item 5. Other Information
Not Applicable
23
Item 6. Exhibits
Exhibits
|
10.1 |
|
Integrated Delivery System Participation Agreement effective as of April 1,
1999 between MDHRS and Humana Medical Plan, Inc., as amended* |
|
|
10.2 |
|
Management Services Agreement dated as of September 1, 2004 between MDHC and
Vista Healthplan, Inc., as amended* |
|
|
10.3 |
|
WCMA Reducing Revolver Loan and Security Agreement dated September 26, 2006,
between Continucare MDHC LLC and Merrill Lynch Business Financial Services, Inc.* |
|
|
10.4 |
|
WCMA Reducing Revolver Loan and Security Agreement dated September 26, 2006,
between Continucare MDHC LLC and Merrill Lynch Business Financial Services, Inc.* |
|
|
10.5 |
|
Amendment of Credit Facility dated September 26, 2006, between Continucare
Corporation and Merrill Lynch Business Financial Services, Inc.* |
|
|
10.6 |
|
Employment Agreement, dated as of October 1, 2006, between Continucare
Corporation and Jose Garcia (incorporated by reference to Exhibit D-1 to the Asset
Purchase Agreement filed as Exhibit 10.1 to Continucares Current Report on Form 8-K
dated May 10, 2006 and filed on May 11, 2006 |
|
|
10.7 |
|
Employment Agreement, dated as of October 1, 2006, between Continucare
Corporation and Dr. Luis Cruz (incorporated by reference to Exhibit D-2 to the Asset
Purchase Agreement filed as Exhibit 10.1 to Continucares Current Report on Form 8-K
dated May 10, 2006 and filed on May 11, 2006) |
|
|
10.8 |
|
Employment Agreement, dated as of October 1, 2006, between Continucare
Corporation and Carlos Garcia (incorporated by reference to Exhibit D-3 to the Asset
Purchase Agreement filed as Exhibit 10.1 to Continucares Current Report on Form 8-K
dated May 10, 2006 and filed on May 11, 2006) |
|
|
31.1 |
|
Section 302 Certification of the Chief Executive Officer. |
|
|
31.2 |
|
Section 302 Certification of the Chief Financial Officer. |
|
|
32.1 |
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
32.2 |
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002. |
24
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
|
|
|
|
|
CONTINUCARE CORPORATION
|
|
Dated: November 13, 2006 |
By: |
/s/ Richard C. Pfenniger, Jr.
|
|
|
|
Richard C. Pfenniger Jr. |
|
|
|
Chairman of the Board, Chief Executive
Officer and President |
|
|
|
|
|
|
By: |
/s/ Fernando L. Fernandez
|
|
|
|
Fernando L. Fernandez |
|
|
|
Senior Vice President Finance, Chief Financial Officer, Treasurer and Secretary |
|
25
EXHIBIT INDEX
|
|
|
|
|
Description
|
|
Exhibit Number
|
|
|
|
|
Integrated Delivery System Participation Agreement
effective as of April 1, 1999 between MDHRS and Humana
Medical Plan, Inc., as amended*
|
|
|
10.1 |
|
|
|
|
|
|
Management Services Agreement dated as of September 1, 2004
between MDHC and Vista Healthplan, Inc., as amended*
|
|
|
10.2 |
|
|
|
|
|
|
WCMA Reducing Revolver Loan and Security Agreement dated
September 26, 2006, between Continucare MDHC LLC and
Merrill Lynch Business Financial Services, Inc.*
|
|
|
10.3 |
|
|
|
|
|
|
WCMA Reducing Revolver Loan and Security Agreement dated
September 26, 2006, between Continucare MDHC LLC and
Merrill Lynch Business Financial Services, Inc.*
|
|
|
10.4 |
|
|
|
|
|
|
Amendment of Credit Facility dated September 26, 2006,
between Continucare Corporation and Merrill Lynch Business
Financial Services, Inc.*
|
|
|
10.5 |
|
|
|
|
|
|
Section 302 Certification of the Chief Executive Officer
|
|
|
31.1 |
|
|
|
|
|
|
Section 302 Certification of the Chief Financial Officer
|
|
|
31.2 |
|
|
|
|
|
|
Certification Pursuant to 18 U.S.C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002
|
|
|
32.1 |
|
|
|
|
|
|
Certification Pursuant to 18 U.S.C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002
|
|
|
32.2 |
|
*filed herewith